The estimated Net Worth of Pharmaceutical Holdings Llc... is at least $13.1 Milion dollars as of 14 May 2020. Pharmaceutical Llc owns over 200,000 units of Altimmune Inc stock worth over $12,097,583 and over the last 5 years Pharmaceutical sold ALT stock worth over $958,000.
Pharmaceutical has made over 1 trades of the Altimmune Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Pharmaceutical sold 200,000 units of ALT stock worth $958,000 on 14 May 2020.
The largest trade Pharmaceutical's ever made was selling 200,000 units of Altimmune Inc stock on 14 May 2020 worth over $958,000. On average, Pharmaceutical trades about 200,000 units every 0 days since 2020. As of 14 May 2020 Pharmaceutical still owns at least 1,687,250 units of Altimmune Inc stock.
You can see the complete history of Pharmaceutical Llc stock trades at the bottom of the page.
Pharmaceutical's mailing address filed with the SEC is 400 OYSTER BLVD., SUITE 202, , SOUTH SAN FRANCISCO, CA, 94080.
Over the last 7 years, insiders at Altimmune Inc have traded over $2,557,810 worth of Altimmune Inc stock and bought 3,362,060 units worth $23,898,779 . The most active insiders traders include Bioventures Ltd Novartis Ag..., Healthcare Capital Partners... a Mitchel Sayare. On average, Altimmune Inc executives and independent directors trade stock every 35 days with the average trade being worth of $432,889. The most recent stock trade was executed by David Drutz on 19 August 2024, trading 41,750 units of ALT stock currently worth $106,463.
altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current
Altimmune Inc executives and other stock owners filed with the SEC include: